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Objective:  To  present  surveillance  data  on  advanced  disease  (AD)  and  late  presentation  (LP)  of HIV  in
Spain  and  their  determinants.
Methods: We  included  all new  HIV diagnoses  notiﬁed  by  the  autonomous  regions  that  consistently
reported  such  cases  throughout  the  period  2007–2011.  Coverage  was  54%  of  the  total  Spanish  population.
Data  sources  consisted  of  clinicians,  laboratories  and  medical  records.  AD was  deﬁned  as  the  presence  of
a CD4  cell  count  <200  cells/L  in the  ﬁrst test  after  HIV  diagnosis,  while  LP  was  deﬁned  as  the  presence
of  a CD4  cell  count  <350  cells/L  after  HIV  diagnosis.  Odds  ratios  and  their  95%  conﬁdence  intervals  (OR,
95%  CI) were  used  as  the measure  of  association.  Logistic  regressions  were  ﬁt  to identify  predictors  of  AD
and LP.
Results:  A  total  of  13,021  new  HIV  diagnoses  were  included.  Among  these,  data  on the  outcome  variable
were  available  in 87.7%.  The  median  CD4  count  at  presentation  was 363  (interquartile  range,  161–565).
Overall,  3356  (29.4%)  patients  met  the  deﬁnition  of  AD  and  5494  (48.1%)  were  classiﬁed  as  LP.  Both  AD  and
LP  increased  with  age  and  were  associated  with  male  sex  and  infection  through  drug  use  or heterosexual
contact.  All  immigrants  except  western  Europeans  were  more  prone  to AD and LP.  Multivariate  models
disaggregated  by  sex showed  that  the  effect  of  age  and region  of  origin  was  weaker  in  women  than  in
men.
Conclusions:  Despite  universal  health  care  coverage  in Spain,  men,  immigrants  and  people  infected
through  drug  use or heterosexual  contact  seem  to be  experiencing  difﬁculties  in  gaining  timely  access  to
HIV care.
©  2013  SESPAS.  Published  by Elsevier  España,  S.L.  All rights  reserved.
Determinantes  de  enfermedad  avanzada  y  presentación  tardía  en  los  nuevos
diagnósticos  de  VIH  notiﬁcados  al  sistema  de  vigilancia  epidemiológica
en  Espan˜a
r  e  s  u  m  e  nalabras clave:
IH
Objetivo:  Se  presentan  los  datos  de  vigilancia  sobre  enfermedad  avanzada  y presentación  tardía  de  los
nuevos  diagnósticos  de  VIH  en  Espan˜a,  y sus  determinantes.
odos  los nuevos  diagnósticos  de  VIH  de  2007–2011  en  el ámbito  de las  comu-nfermedad avanzada Métodos: Se incluyeron  t
resentación tardía
span˜a
igilancia epidemiológica
nidades  autónomas  que notiﬁcaron  de  forma  constante  durante  todo  el  periodo  (54% de la  población
espan˜ola).  La fuente  de  información  fueron  clínicos  y  laboratorios.  Se  deﬁnió  como  enfermedad  avanzada
un recuento  <  200  linfocitos  CD4/l  en  la primera  determinación  tras  el diagnóstico,  y  como  presentación
tardía  <  350 linfocitos  CD4/l.  Se usaron  la  odds  ratio  y su intervalo  de  conﬁanza  del  95%  como  medida
∗ Corresponding author.
E-mail address: jaoliva@isciii.es (J. Oliva).
213-9111/$ – see front matter © 2013 SESPAS. Published by Elsevier España, S.L. All rights reserved.
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de  asociación.  Para  el  análisis  multivariado  de  los  factores  asociados  a enfermedad  avanzada  y pre-
sentación  tardía  se  ajustó  un  modelo  de  regresión  logística.
Resultados:  Se  incluyeron  13.021  nuevos  diagnósticos,  de los  cuales  el 87,7%  tenía información  de  la  va-
riable  de  estudio.  La mediana  de  CD4  fue de 363  (rango  intercuartílico:  161–565).  Durante  el periodo,  3.356
pacientes  (29,4%)  cumplían  la  deﬁnición  de  enfermedad  avanzada  y  5.494  (48.1%)  se clasiﬁcaron  como
presentación  tardía.  Tanto  la  enfermedad  avanzada  como  la presentación  tardía  aumentaban  con la  edad,
se  asociaban  al  sexo  masculino  y  a la  transmisión  a través  del uso  de  drogas  inyectadas  o heterosexual.
Ser inmigrante  de  cualquier  origen,  excepto  de  Europa  Occidental,  se  asociaba  a enfermedad  avanzada  y
presentación  tardía.  Desagregando  por  sexo,  el efecto  de  la  edad  y  de la  región  de  origen  fue  más débil  en
las  mujeres  que en  los hombres.
Conclusión:  A  pesar  de  la  cobertura  universal  en  Espan˜a,  los hombres,  los  inmigrantes,  los  usuarios  de
drogas  inyectadas  y las  personas  infectadas  por  relaciones  heterosexuales  parecen  tener más  diﬁcultad
to  clí
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Early HIV diagnosis and treatment are essential in the control of
he HIV epidemic worldwide. HIV-infected patients presenting late
n the course of their infection have higher rates of morbidity and
ortality and require more healthcare resources than those pre-
enting earlier.1,2 Furthermore, HIV diagnosis motivates infected
eople to adopt measures to reduce the risk of infecting others,
nd treatment with highly active antiretroviral therapy (HAART)
as been shown to greatly reduce HIV transmission.3–5
Different criteria have been used in the literature to deﬁne diag-
ostic delay and late presentation among HIV-infected patients,
hich generally include the level of CD4 cells and the pres-
nce/absence of AIDS-deﬁning diseases.6 Recently, European
roups have proposed that “late presentation” be deﬁned as the
resence of an AIDS condition or CD4 cell count <350 cells/L
t presentation for care, leaving the term “advanced disease” to
escribe the presence of either an AIDS condition or a CD4 cell count
200 cells/L at presentation.7,8
Late presentation remains a major challenge for the control of
IV in Europe, and reducing the time between infection and entry to
are is a priority for the region.9–11 Measuring CD4 cells at presen-
ation for care is routine practice in most countries – in particular
n the Western part of the region. But, in 2011, only 56% of new
IV diagnoses reported to the European Centre for Disease Control
ECDC) from the EU countries had CD4 data.12
In Spain, epidemiological surveillance on new HIV diagnosis
s performed through the Sistema de Información sobre Nuevos
iagnósticos de VIH (SINIVIH in its Spanish acronym) which col-
ects epidemiological and clinical data on people newly diagnosed
ith HIV. This system, expected to be implemented countrywide
n the near future, currently includes data from 17 out of 19 of
pain’s autonomous regions (AR). CD4 cell count at presentation is
ollected, and the completion of the variable is good.
Previously published SINIVIH data showed that almost 40% of
ew HIV diagnoses during the period 2003–2007 had <200 CD4,
nd that this situation was more likely to occur in men, people over
0 years, intravenous drug users (IDU) and heterosexuals; factors
ssociated with having <200 CD4 were the same in Spaniards and
igrants, but the association was stronger in the latter group.13
The objectives of this paper are to present data on the immuno-
ogical situation of the new HIV diagnoses reported to the SINIVIH
n the period 2007–2011, and to determine whether predictors
or having <200 CD4 at entry to care are different from predictors
f having <350 CD4.ethods
All people newly diagnosed with HIV – according to the Euro-
ean case deﬁnition14 – and reported during the period 2007–2011nico.
ESPAS.  Publicado  por Elsevier  España,  S.L.  Todos  los  derechos  reservados.
to the SINIVIH in the AR of Asturias, Balearic Islands, Canary Islands,
Catalonia, Ceuta, Extremadura, Galicia, Madrid, Navarre, Basque
Country and La Rioja, were included in the study. These regions
comprise 54% of the total Spanish population and were selected for
the analysis because they reported to the SINIVIH during the whole
study period.
Information was collected, using the standard surveillance
forms, on the following variables: date of HIV diagnosis, date of
notiﬁcation, age, gender, reporting autonomous region, transmis-
sion mode, ﬁrst CD4 cell count performed after HIV diagnosis and
country or subcontinent of origin. Data sources were the attending
clinicians and the laboratories, and information was completed by
reviewing clinical records where necessary.
The study was performed according to the Spanish legislation
on data protection which does not require informed consent for
the collection of surveillance data, as is the case in this study (Ley
33/2011, de 4 de octubre, General de Salud Pública, artículo 41.2).
Elimination of duplicate reports was made in each AR by public
health staff, but inter-regional duplicates were not eliminated since
data were sent without personal identiﬁers to the National Center
of Epidemiology, where the analysis was  performed.
For the purpose of this study, “advanced HIV disease” (AD) was
deﬁned as the presence of a CD4 count below 200 cells/L in the
ﬁrst analysis performed after HIV diagnosis. “Late presentation”
(LP) was deﬁned as the presence of a CD4 count below 350 cells/L
in the ﬁrst analysis performed after HIV diagnosis.
Data distributions by variables related to person, place and time
were performed. The 2 test was  used to evaluate the associa-
tion between categorical variables. The odds ratio (OR) and its 95%
conﬁdence interval (95%CI) were used as the measure of associa-
tion. To identify variables associated with AD or LP, multivariable
logistic regression models were ﬁt in the overall population and
disaggregated by sex; for these models only cases with informa-
tion on CD4 were used. Additionally, in order to assess the potential
bias introduced by excluding sicker patients without a CD4 count, a
sensitivity analysis was performed, assuming that all patients with-
out a CD4 count were late presenters. All statistical analyses were
performed using Stata Statistical Software: Release 11.1, College
Station, TX: Stata Corporation (2009).
Results
A total of 13,021 new HIV cases were reported during the study
period, of which 11,426 (87.7%) had information on CD4 cell count
at presentation. The majority (81%) of the new HIV diagnoses were
male, and 83.4% had been infected through sexual contact, espe-
cially through sex between men; the median age at diagnosis
was 35 years (inter-quartile range: 29–43). Cases with information
on CD4 count differed from those without this information with
regard to transmission mode, region of origin and year or diagnosis:
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Table 1
Characteristics of new HIV diagnoses. Spain,a 2007–2011.
Characteristics Total cases
n  (%)
Cases with CD4 cell count
n (%)
Cases without CD4 cell count
n (%)
Sex
Female 2471 (19.0) 2148 (18.8) 322 (20.2)
Male  10,550 (81.0) 9278 (81.2) 1273 (79.8)
Age  at HIV diagnosis (years)b
All 35 (29–43) 35 (29–43) 34 (28–42)
Female 34 (28–42) 34 (28–42) 34 (28–41)
Male  35 (29–43) 35 (29–43) 34 (28–42)
Transmission modec
MSM  6435 (49.4) 5846 (51.2) 589 (36.9)
IDU  981 (7.5) 837 (7.3) 145 (9.1)
Hetero 4423 (34.0) 4021 (35.2) 401 (25.1)
Other  61 (0.5) 49 (0.4) 12 (0.8)
Unknown/NA 1121 (8.6) 673 (5.9) 448 (28.1)
Region of originc
Spain 7862 (60.4) 6943 (60.8) 920 (57.7)
Western Europe 586 (4.5) 509 (4.5) 77 (4.8)
Eastern Europe 380 (2.9) 311 (2.7) 69 (4.3)
Latin  America 2811 (21.6) 2501 (21.9) 309 (19.4)
Sub-Saharan Africa 1120 (8.6) 936 (8.2) 184 (11.5)
North Africa 137 (1.1) 118 (1.0) 19 (1.2)
Other/NA 125 (1.0) 108 (0.9) 17 (1.1)
Year  of diagnosisc
2007 2513 (19.3) 2204 (19.3) 309 (19.4)
2008  2847 (21.9) 2553 (22.3) 294 (18.4)
2009  2625 (20.2) 2347 (20.5) 278 (17.4)
2010  2746 (21.1) 2341 (20.5) 405 (25.4)
2011  2290 (17.6) 1981 (17.3) 309 (19.4)
Total  13,021 (100) 11,426 (100) 1595 (100)
HIV: human immunodeﬁciency virus; MSM:  men  who have sex with men; IDU: injecting drug use; hetero: heterosexual contact; NA: not available.
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b Median (inter quartile range).
c p-Value <0.05. Differences between cases with and without CD4 cell count.
ub-Saharan migrants and injecting drug users (IDU) were over-
epresented among people lacking this information; furthermore,
he proportion of cases with unknown information on transmission
ode was higher among those without data on CD4 count (Table 1).
Median CD4 at presentation was 363 (inter-quartile range:
61–565). Overall, 3356 (29.4%) patients met  the deﬁnition of AD.
he proportion of patients with AD was higher in women, increased
ith age, and was highest among cases whose transmission mode
as IDU or heterosexual as compared with men  who  have sex
ith men  (MSM). By region of origin, AD prevalence was  generally
reater in migrants than in Spaniards (Table 2). In the multivariate
nalysis of the global data the probability of having AD was  higher
n men  (OR: 1.3; 95%CI: 1.1–1.5), in the age groups 30–39 years
OR: 1.7; 95%CI: 1.5–1.9), 40–49 years (OR: 2.8; 95%CI: 2.5–3.2)
nd ≥50 years (OR: 4.4; 95%CI: 3.8–5.1), as compared to the age
roup 20–29 years; in people originating from East Europe (OR:
.7; 95%CI: 1.3–2.1), Latin America (OR: 1.4; 95%CI: 1.3–1.6), Sub-
aharan Africa (OR: 1.4; 95%CI: 1.2–1.7), and North Africa (OR: 1.6;
5%CI: 1.1–2.4); and among IDU (OR: 2.0; 95%CI: 1.7–2.4) and those
nfected by heterosexual contact (OR: 2.4; 95%CI: 2.1–2.7) (Table 3).
A total of 5494 (48.1%) subjects presented late. The groups most
ffected by LP were the same as those affected by AD and the
ssociations were in the same direction; nevertheless in the multi-
ariate analysis there were slight differences in the strength of the
ssociations (Tables 2 and 3).
When disaggregating by sex, the multivariate analyses show dif-
erent effect of age and region of origin in men  than in women. In
en, AD and LP clearly increase for cases older than 29 while among
omen the effect is weaker and the increase in the age group 30–
9 is on the edge of statistical signiﬁcance. The effect of region of
rigin is also weaker in women than in men  (Tables 4 and 5).ioja, Madrid, Navarre, and Basque Country.
When the sensitivity analysis assuming that cases without
information on CD4 were late presenters was  performed factors
associated with AD and LP did not change.
Discussion
This study presents surveillance data on CD4 count at presen-
tation for care in new HIV diagnoses in a setting covering 54% of
the total Spanish population. The results show that subjects who
had information on CD4 cell count are different from those who did
not, that almost half of new HIV diagnoses presented late to med-
ical care and 30% had AD, and that predictors of LP and AD are the
same.
Surveillance data on CD4 count at entry into care are scarce in
the EU.12 In this study information was  available in almost 90% of
registries; however, the results show that the lack of information is
not randomly distributed, suggesting that traditionally disadvan-
taged subjects, such as IDU and migrants, might have problems in
accessing care after being diagnosed, even if they are entitled to
free heath care, as is the case in Spain.
The prevalence of AD and LP is similar to that found in
France or the UK, and higher than the ﬁgures reported in The
Netherlands or the Czech Republic.12 Outside the EU, studies car-
ried out – using the same deﬁnition – in the United States and Hong
Kong report a greater proportion of AD.15,16
In Spain, HIV testing is part of routine prenatal care, and this
probably explains, at least to some extent, why women are less
likely to present late. The fact that (as shown in the multivariate
analyses disaggregated by sex) the effect of age and region of ori-
gin on AD and LP are weaker in women than in men also support
this explanation. This has also been observed in other developed
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Table  2
Advanced HIV disease and late presentation in new HIV diagnoses. Spain,a 2007–2011.
Characteristics Number of cases with CD4 cell count
n  (% completeness in each category)
Advanced HIV disease
(<200 cell/L)
Late presentation
(<350 cell/L)
n (%) n (%)
Sex
Female 2148 (86.9) 727 (33.8) 1131 (52.6)
Male  9278 (87.9) 2629 (28.4) 4363 (47.0)
Age  (years)
0–19 206 (85.1) 22 (10.7) 47 (22.8)
20–29 3040 (87.1) 532 (17.5) 1132 (37.2)
30–39 4197 (87.5) 1130 (26.9) 1912 (45.6)
40–49 2604 (88.2) 982 (37.7) 1479 (56.8)
≥50 1379 (89.7) 690 (50.0) 924 (67.0)
Transmission mode
MSM 5846 (90.8) 1193 (20.4) 2285 (39.1)
IDU  837 (85.3) 285 (34.5) 445 (53.2)
Hetero 4021 (90.9) 1587 (39.5) 2365 (58.8)
Other 49 (80.3) 16 (32.7) 20 (40.8)
Unknown/NA 673 (60.0) 275 (40.8) 379 (56.3)
Region of origin
Spain 6943 (88.3) 1916 (27.6) 3121 (44.9)
Western Europe 509 (86.9) 138 (27.1) 232 (45.6)
Eastern Europe 311 (81.8) 108 (34.7) 154 (49.5)
Latin  America 2501 (89.0) 736 (29.4) 1278 (51.1)
Sub-Saharan Africa 936 (83.6) 369 (39.4) 581 (62.1)
North Africa 118 (86.1) 49 (41.5) 68 (57.6)
Other/NA 108 (86.4) 40 (37.0) 60 (55.6)
Year  of diagnosis
2007 2204 (87.7) 688 (31.2) 1110 (50.4)
2008 2553 (89.7) 753 (29.5) 1235 (48.4)
2009 2347 (89.4) 723 (30.8) 1187 (50.6)
2010 2341 (85.3) 641 (27.4) 1063 (45.4)
2011  1981 (86.5) 551 (27.8) 899 (45.4)
Total  11,426 (87.8) 3356 (29.4) 5494 (48.1)
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sIV: Human immunodeﬁciency virus; MSM:  men  who  have sex with men; IDU: inj
a Asturias, Balearic Islands, Canary Islands, Catalonia, Ceuta, Extremadura, Galicia
ountries where antenatal HIV screening is the rule.17 Data from
he United Kingdom show that median CD4 at HIV diagnosis is sig-
iﬁcantly higher in pregnant women than in women diagnosed in
ther units and in heterosexual men.18
The association of AD with age is already known.13,15,16,19–25
ge is also associated with LP. The most widely accepted explana-
ion is that risk perception and frequency of testing decrease with
ncreasing age.20,25 Another possible explanation relates to the nat-
ral history of the disease, which clinically and immunologically
volves more rapidly in older patients.25
In comparison with other transmission modes, MSM  are the
east likely to present late, while people infected through het-
rosexual contact are more likely, ﬁndings also common to other
ountries.16,21,23,24 These results probably reﬂect risk perceptions
n the part of both patients and providers, and point to the need
o scale up HIV testing among heterosexuals, in particular among
en.
Spain experienced overlapping epidemics of HIV and heroin
njection from the 1980s to the mid-1990s.26 The high likelihood
f AD/LP in IDU is surprising, since risk perception in this group is
ery high and HIV testing is routinely offered to patients in drug
reatment centers, prisons and at all contacts with the health care
ystem. A possible explanation could be that rather than being the
onsequence of late diagnosis this ﬁnding is the result of worse
inkage to care among IDU due to barriers in accessing care speciﬁc
o this group. The fact that in our data, the proportion of IDU with a
D4 count performed within the ﬁrst 3 months after HIV diagnosis
s lower than for other transmission modes (60% vs. 77%, p < 0.05)
upports this explanation. drug use; hetero: heterosexual contact; NA: not available.
ioja, Madrid, Navarre, and Basque Country.
Previously published studies, both in Spain and abroad, iden-
tify being a migrant as a risk factor for late HIV diagnosis and
presentation for care.13,19,27,28 Worries about discrimination, lan-
guage barriers, the perception of HIV as a deadly disease, and lack
of conﬁdence about the conﬁdentiality of results have been noted
as barriers for HIV testing among migrants,29,30 and migrants, in
particular illegal migrants, have restricted access to care in most
countries.31 Some of these factors might be operating in Spain, even
though all migrants are entitled to HIV care on the same basis as
Spaniards. On the other hand, immigration is a very recent phe-
nomenon in Spain and it is possible that, to some extent, ﬁgures for
AD and LP in immigrants reﬂect factors operating in their country of
origin rather than in Spain. Unfortunately, date of entry into Spain
is not yet collected in the SINIVIH; thus this hypothesis cannot be
explored further.
This study has some limitations. The results cannot be extrap-
olated to the whole country because data are not countrywide.
Nevertheless, study coverage is high, under-reporting is estimated
to be moderate, and participating AR do not differ from the rest in
terms of factors inﬂuencing AD/LP, since HIV care is provided free
of charge, in the context of a universal health care system, in the
whole country. Furthermore, due to the lack of information on the
concomitant diagnosis of AIDS and HIV, it could be argued that our
data underestimate AD and LP, since some authors include pres-
ence of AIDS as an additional deﬁning criteria for the two events.7While it is true that this information is not currently available in
all participating AR, some do collect it; analysis of available data
show that if this criterion were included in the deﬁnition of AD and
LP, the proportion of AD in our data would increase from 29.4% to
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Table 3
Factors associated with advanced disease and late presentation in newly diagnosed HIV infections. Spain,a 2007–2011. N = 11,426.
Characteristics Advanced HIV disease (<200 cell/L)b Late presentation (<350 cell/L)b
Adjusted OR 95%CI Adjusted OR 95%CI
Sex
Female 1 1
Male  1.3 (1.1–1.5) 1.4 (1.2–1.5)
Age  (years)
0–19 0.4 (0.3–0.7) 0.5 (0.3–0.7)
20–29 1 1
30–39  1.7 (1.5–1.9) 1.4 (1.2–1.5)
40–49  2.8 (2.5–3.2) 2.2 (2.0–2.5)
≥50 4.4 (3.8–5.1) 3.3 (2.9–3.8)
Transmission mode
MSM  1 1
IDU  2.0 (1.7–2.4) 1.9 (1.6–2.2)
Hetero 2.4 (2.1–2.7) 2.1 (1.9–2.4)
Unknown/NA 2.3 (1.9–2.8) 1.8 (1.5–2.1)
Region of origin
Spain 1 1
Western Europe 1.1 (0.9–1.3) 1.1 (0.9–1.3)
Eastern Europe 1.7 (1.3–2.1) 1.3 (1.1–1.7)
Latin  America 1.4 (1.3–1.6) 1.6 (1.5–1.8)
Sub-Saharan Africa 1.4 (1.2–1.7) 1.7 (1.5–2.0)
North Africa 1.6 (1.1–2.4) 1.5 (1.0–2.1)
Year  of diagnosis
2011 1 (0.9–1.2) 1 (1.0–1.3)
2007 1.1 (0.8–1.1) 1.1 (0.9–1.2)
2008 1.0 (0.9–1.2) 1.0 (1.0–1.3)
2009 1.1 (0.8–1.1) 1.2 (0.8–1.1)
2010 0.9 0.9
VIH: Human immunodeﬁciency virus; OR: odds ratio; CI: conﬁdence interval; MSM: men  who have sex with men; IDU: injecting drug use; hetero: heterosexual contact;
NA:  not available.
a Asturias, Balearic Islands, Canary Islands, Catalonia, Ceuta, Extremadura, Galicia, La Rioja, Madrid, Navarre, and Basque Country.
b Multivariable logistic regression, OR and 95% CIs adjusted for all listed variables and reporting Autonomous Region.
Table 4
Factors associated with advanced disease and late presentation in newly diagnosed HIV infections in men. Spain,a 2007–2011. N = 9278.
Characteristics Advanced HIV disease (<200 cell/L)b Late presentation (<350 cell/L)b
Adjusted OR 95%CI Adjusted OR 95%CI
Age (years)
0–19 0.5 (0.3–1.0) 0.6 (0.4–0.9)
20–29 1 1
30–39  1.9 (1.6–2.2) 1.4 (1.3–1.6)
40–49  3.1 (2.7–3.6) 2.2 (2.0–2.5)
≥50  5.3 (4.5–6.3) 3.7 (3.2–4.4)
Transmission mode
Hetero 1 1
IDU  0.9 (0.7–1.1) 0.9 (0.8–1.1)
MSM  0.4 (0.3–0.5) 0.5 (0.4–0.6)
Unknown/NA 1.0 (0.8–1.2) 0.8 (0.7–1.0)
Region of origin
Spain 1 1
Western Europe 1.1 (0.9–1.3) 1.1 (0.9–1.3)
Eastern Europe 1.7 (1.2–2.3) 1.3 (1.0–1.8)
Latin America 1.5 (1.3–1.7) 1.6 (1.5–1.8)
Sub-Saharan Africa 1.7 (1.4–2.1) 2.1 (1.7–2.7)
North Africa 1.6 (1.1–2.5) 1.3 (0.8–2.0)
Year  of diagnosis
2011 1 (1.0–1.3) 1 (1.0–1.3)
2007 1.1 (0.9–1.2) 1.2 (0.9–1.2)
2008 1.0 (1.0–1.3) 1.1 (1.1–1.4)
2009  1.1 (0.8–1.1) 1.3 (0.9–1.2)
2010 1.0 1.0
VIH: Human immunodeﬁciency virus; OR: odds ratio; CI: conﬁdence interval; MSM: men  who have sex with men; IDU: injecting drug use; hetero: heterosexual contact;
NA:  not available.
a Asturias, Balearic Islands, Canary Islands, Catalonia, Ceuta, Extremadura, Galicia, La Rioja, Madrid, Navarre, and Basque Country.
b Multivariable logistic regression, OR and 95%CIs adjusted for all listed variables and reporting Autonomous Region.
J. Oliva et al. / Gac Sanit. 2014;28(2):116–122 121
Table  5
Factors associated with advanced disease and late presentation in newly diagnosed HIV infections in women. Spain,a 2007–2011. N = 2148.
Characteristics Advanced HIV disease (<200 cell/L)b Late presentation (<350 cell/L)b
Adjusted OR 95%CI Adjusted OR 95%CI
Age (years)
0–19 0.4 (0.2–0.8) 0.3 (0.1–0.5)
20–29 1 1
30–39 1.2 (1.0–1.6) 1.2 (1.0–1.5)
40–49  2.0 (1.6–2.7) 1.9 (1.5–2.5)
≥50  2.2 (1.6–3.0) 2.0 (1.5–2.8)
Transmission mode
Hetero 1 1
IDU  0.8 (0.5–1.1) 0.8 (0.6–1.1)
Unknown/NA 1.3 (0.8–2.1) 1.2 (0.8–1.9)
Region of origin
Spain 1 1
Western Europe 1.2 (0.7–2.3) 1.3 (0.7–2.4)
Eastern Europe 1.5 (0.9–2.3) 1.3 (0.9–2.0)
Latin  America 1.3 (1.1–1.7) 1.5 (1.2–1.9)
Sub-Saharan Africa 1.1 (0.8–1.4) 1.3 (1.0–1.7)
North Africa 1.6 (0.7–3.5) 2.0 (0.9–4.4)
Year  of diagnosis
2011 1 (0.6–1.1) 1 (0.7–1.2)
2007 0.8 (0.6–1.0) 0.9 (0.6–1.1)
2008 0.8 (0.6–1.1) 0.8 (0.6–1.1)
2009 0.8 (0.5–1.0) 0.8 (0.5–1.0)
2010 0.7 0.7
V  injecting drug use; hetero: heterosexual contact; NA: not available.
, La Rioja, Madrid, Navarre, and Basque Country.
 and reporting Autonomous Region.
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What is known on this topic?
Advanced disease and late presentation remains a major
challenge for the control of HIV. Reducing time between infec-
tion and entry to care is a priority. In Spain, epidemiological
surveillance on new HIV diagnosis is performed through the
Sistema de Información sobre Nuevos Diagnósticos de VIH
which collects epidemiological and clinical data on people
newly diagnosed.
What does this study add to the literature?
In Spain, data on CD4 count at entry into care were available
in almost 90% of new HIV diagnoses notiﬁed to the surveillance
system in the period 2007–2011. Some socially disadvantaged
groups, such as IDU and migrants, were more likely to have
missing data on CD4 count, suggesting that they might
have problems in accessing care after being diagnosed. In the
study one out of two new HIV diagnoses in Spain presented late
for care. Male patients, migrants and people infected through
heterosexual contact or sharing of injection equipment wereIH: Human immunodeﬁciency virus; OR: odds ratio; CI: conﬁdence interval; IDU:
a Asturias, Balearic Islands, Canary Islands, Catalonia, Ceuta, Extremadura, Galicia
b Multivariable logistic regression, OR and 95% CIs adjusted for all listed variables
2.7%, and the proportion of LP from 48.1% to 50.0%. On the other
and, since the SINIVIH has been implemented only recently in
ome of the participating AR, it is possible that some cases reported
s new HIV diagnoses in the study period were actually previously
iagnosed patients falsely classiﬁed as new due to the lack of an
stablished HIV case registry; if this were the case, both AD and
P may  be overestimated in this study. Finally, duplicates within
ach autonomous region have been eliminated but this is not the
ase with those within autonomous regions. We  think that between
–10% of registries could be duplicated, in which case the incidence
f new HIV diagnoses would be overestimated; however, it is not
lear how this would affect late presentation and factors associated
ith it. Nevertheless we expect to be able to eliminate duplicates
ithin autonomous regions in the near future.
In summary, this study shows that one out of two  new HIV diag-
oses in Spain presents late for care, and that some sub-populations
re more vulnerable than others to this problem. Recently, guide-
ines for scaling-up HIV testing have been published by some
uropean countries and the ECDC.32 In Spain, a working group aim-
ng to accomplish a similar task, including appropriate linkage to
IV care, has been appointed. Hopefully, implementation of guide-
ines in the near future will help to decrease late access to HIV
iagnosis and care. Finally, enhanced surveillance, coupled with
mplementation of SINIVIH in the whole country, is essential to
onitor guidelines implementation and provide better informa-
ion on LP and its determinants at both national and international
evels.
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